Home Forums Marketplace Table of Contents Events Member List Site Map Register Mark Forums Read



Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.


BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis

Reply
Submit Thread >  Submit to Digg Submit to Reddit Submit to Furl Submit to Del.icio.us Submit to Google Submit to Yahoo! This Submit to Technorati Submit to StumbleUpon Submit to Spurl Submit to Netscape  < Submit Thread
 
Thread Tools Display Modes
  #1  
Old 5th September 2008, 06:01 AM
RSSFeedBot RSSFeedBot is offline
I, Robot
 
About:
Join Date: Jul 2008
Posts: 3,060
Join Date: Jul 2008
Marketplace reputation 0% (0)
CPD Points: 1
Thanks: 0
Thanked 5 Times in 5 Posts
Default BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis

Podiatry Arena members do not see these ads
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced results from the completed Phase IIa trial of BCX-4208 in patients with moderate to severe plaque psoriasis. Consistent with interim findings reported in May 2008, this study of BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase (PNP) inhibitor, met its primary objectives of safety and tolerability.

More...
Reply With Quote
Sponsored Links
Reply



Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Translate This Page

Similar Threads
Thread Thread Starter Forum Replies Last Post
Results of triple arthrodesis NewsBot Foot Surgery 1 13th August 2008 04:03 PM
The Journal of Irreproducible Results Kevin Kirby Break Room 3 9th August 2007 08:00 AM
Vascular Involvement in Diabetic Subjects with Ischemic Foot Ulcer NewsBot Diabetic Foot & Wound Management 0 2nd January 2007 07:31 AM


New To Site? Need Help?

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.


All times are GMT -7. The time now is 12:55 PM.